Cataliq Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 31 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 24-10-2024
- Revenue 6.57%
(FY 2023)
- Profit 15.44%
(FY 2023)
- Ebitda 12.71%
(FY 2023)
- Net Worth 16.07%
(FY 2023)
- Total Assets 14.68%
(FY 2023)
About Cataliq Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.00 M.
Randhir Patwari, Nayna Patwari, Nilay Patwari, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231GJ1993PTC019219
- Company No.
019219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cataliq Laboratories Private Limited offer?
Cataliq Laboratories Private Limited offers a wide range of products and services, including Laboratory & Lab Equipment, Laboratory Consumables, Brain & Nervous System Drugs, Psychotherapeutic Agents.
Who are the key members and board of directors at Cataliq Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilay Patwari  | Director | 01-Jul-2009 | Current |
| Randhir Patwari | Director | 30-Mar-1993 | Current |
| Nayna Patwari | Director | 30-Mar-1993 | Current |
| Mansi Patwari | Director | 13-Nov-2018 | Current |
Financial Performance of Cataliq Laboratories.
Cataliq Laboratories Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.57% increase. The company also saw a substantial improvement in profitability, with a 15.44% increase in profit. The company's net worth Soared by an impressive increase of 16.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cataliq Laboratories?
In 2023, Cataliq Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Nov 2022 | ₹1.00 M | Open |
How Many Employees Work at Cataliq Laboratories?
Unlock and access historical data on people associated with Cataliq Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cataliq Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cataliq Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
